MedTrace Logo

New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day

NCT01360021 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 214

Last updated 2014-03-11

Study results available
· View outcomes & findings →

Summary

This is a comparison of the efficacy of the Symbicort breath actuated dose inhaler to the Symbicort pressured meter dose inhaler after 12 weeks of a twice a day dose.

Conditions

Interventions

DRUG

Symbicort

Breath actuated metered dose inhaler

DRUG

Symbicort

Actuation counter pressured metered dose inhaler

DRUG

Budesonide

Actuation counter pressured metered dose inhaler

Sponsors & Collaborators

Principal Investigators

  • Goran Eckerwall, MD · AstraZeneca R&D, Mölndal

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States
  • Bulgaria
  • Hungary
  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01360021 on ClinicalTrials.gov